BYSI (BeyondSpring Inc. Ordinary Shares)

Insider Trading Activity

Every open-market purchase and sale reported by BYSI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

Form 4 Filings
34
most recent
Open-Market Buys
0
code P
Sales
17
code S
Reporting Insiders
6
current holders
BYSI — Recent Form 4 Transactions (latest 2026-07-06)
FiledInsiderRole TypeSharesValue
2026-07-06 Jiangwen Majeti Director A
2026-07-06 Min Qiu Chief Executive Officer A
2026-05-15 Lan Huang Chief Executive Officer G
2026-04-08 Matthew Kirkby Director A
2026-04-03 Brendan Delaney Director A
2026-04-03 Patrick Fabbio Director A
2026-04-03 Lan Huang Chief Executive Officer A
2026-04-03 Jiangwen Majeti Director A
2026-04-03 Sihai Xu Director A
2026-04-03 Yingjuan June Lu Chief Scientific Officer A
2025-10-20 Decheng Capital China Life Sciences USD Fund II, L.P. 10%+ Owner Sell
2025-10-15 Decheng Capital Global Healthcare GP, LLC 10%+ Owner Sell
2025-10-10 Decheng Capital Global Healthcare Fund (Master), LP 10%+ Owner Sell
2025-10-07 Decheng Capital China Life Sciences USD Fund II, L.P. 10%+ Owner Sell
2025-10-02 Xiangmin Cui 10%+ Owner Sell
2025-09-29 Decheng Capital China Life Sciences USD Fund II, L.P. 10%+ Owner Sell
2025-09-24 Xiangmin Cui 10%+ Owner Sell
2025-09-19 Xiangmin Cui 10%+ Owner Sell
2025-09-16 Decheng Capital China Life Sciences USD Fund II, L.P. 10%+ Owner Sell
2025-09-11 Decheng Capital China Life Sciences USD Fund III, L.P. 10%+ Owner Sell
2025-09-08 Decheng Capital China Life Sciences USD Fund II, L.P. 10%+ Owner Sell
2025-09-03 Decheng Capital China Life Sciences USD Fund II, L.P. 10%+ Owner Sell
2025-08-28 Decheng Capital Global Healthcare GP, LLC 10%+ Owner Sell
2025-08-25 Decheng Capital Management III (Cayman), LLC 10%+ Owner Sell
2025-08-20 Xiangmin Cui 10%+ Owner Sell
2025-08-15 Decheng Capital China Life Sciences USD Fund II, L.P. 10%+ Owner Sell
2025-08-11 Decheng Capital Global Healthcare GP, LLC 10%+ Owner Sell
2025-04-23 Yingjuan June Lu Chief Scientific Officer A
2025-04-23 Brendan Delaney Director A
2025-04-23 Matthew Kirkby Director A
2025-04-23 Lan Huang Chief Executive Officer A
2025-04-23 Jiangwen Majeti Director A
2025-04-23 Patrick Fabbio Director A
2025-04-23 Sihai Xu Director A
BYSI — Current Insider Holders
InsiderRole Shares HeldValue
10%+ Owner 1,913,734
10%+ Owner 1,874,710
10%+ Owner 1,841,297
10%+ Owner 1,617,409
10%+ Owner 1,564,406
10%+ Owner 891,734
How to read Form 4 activity

Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.

Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.

Full filing history and per-insider positions are on the BYSI quote page; the site-wide leaderboard is on the insider transactions hub.